Skok Kristijan, Zidarič Tanja, Orthaber Kristjan, Pristovnik Matevž, Kostevšek Nina, Žužek Rožman Kristina, Šturm Sašo, Gradišnik Lidija, Maver Uroš, Maver Tina
Institute of Biomedical Sciences, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia.
Department of Pathology, Hospital Graz II, Location West, Göstinger Straße 22, 8020 Graz, Austria.
Pharmaceutics. 2022 Mar 22;14(4):689. doi: 10.3390/pharmaceutics14040689.
Despite medical advances, skin-associated disorders continue to pose a unique challenge to physicians worldwide. Skin cancer is one of the most common forms of cancer, with more than one million new cases reported each year. Currently, surgical excision is its primary treatment; however, this can be impractical or even contradictory in certain situations. An interesting potential alternative could lie in topical treatment solutions. The goal of our study was to develop novel multilayer nanofilms consisting of a combination of polyhydroxyethyl methacrylate (PHEMA), polyhydroxypropyl methacrylate (PHPMA), sodium deoxycholate (NaDOC) with incorporated superparamagnetic iron-platinum nanoparticles (FePt NPs), and the potent anticancer drug (5-fluorouracil), for theranostic skin cancer treatment. All multilayer systems were prepared by spin-coating and characterised by atomic force microscopy, infrared spectroscopy, and contact angle measurement. The magnetic properties of the incorporated FePt NPs were evaluated using magnetisation measurement, while their size was determined using transmission electron microscopy (TEM). Drug release performance was tested in vitro, and formulation safety was evaluated on human-skin-derived fibroblasts. Finally, the efficacy for skin cancer treatment was tested on our own basal-cell carcinoma cell line.
Materials (Basel). 2023-3-15
J Nanosci Nanotechnol. 2008-11
Materials (Basel). 2023-3-15
Mol Cancer. 2023-1-12
Biomed Res Int. 2022
ACS Appl Mater Interfaces. 2022-1-26
Nanomaterials (Basel). 2021-3-3
Adv Drug Deliv Rev. 2020-1-1
Adv Drug Deliv Rev. 2020
Toxicol In Vitro. 2019-5-10